<DOC>
	<DOCNO>NCT02517515</DOCNO>
	<brief_summary>This Phase 3 , multicenter , randomize , double-blind , placebo-controlled study evaluate ABT 450/r/ABT-267 ABT-333 treatment-naïve treatment-experienced adult subgenotype 1b chronic HCV .</brief_summary>
	<brief_title>ABT-450/Ritonavir/ABT-267 ( ABT-450/r/ABT-267 ) ABT-333 Treatment-Naïve Treatment-Experienced , Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1 . Chinese , South Korean , Taiwanese descent full Chinese , South Korean , Taiwanese parentage 2 . Chronic HCVinfection prior study enrollment . 3 . Screening laboratory result indicate HCV GT 1b infection . 4 . Per local standard practice , document result one follow : Liver biopsy within 24 month prior screen demonstrate absence cirrhosis , e.g. , Metavir Score ≤ 3 Ishak score ≤ 4 ; A screening FibroTest score ≤ 0.72 Aspartate Aminotransferase Platelet Ratio Index ( APRI ) ≤ 2 ; A screening FibroScan result &lt; 9.6 kPa . ( Participants nonqualifying FibroTest/APRI FibroScan result may enrol qualify liver biopsy perform within 24 month prior screen . ) 5 . Participant never receive antiviral treatment ( include IFNbased therapy [ IFN ( alpha , beta pegIFN ) without RBV ] ) hepatitis C infection ( treatmentnaïve participant ) participant must documentation met definition one follow category ( treatment experience participant ) : Nonresponder Relapser 6 . Participant plasma HCV RNA level &gt; 10,000 IU/mL Screening . 1 . HCV genotype perform screen indicate unable genotype infection HCV genotype . 2 . Positive test result Screening hepatitis B surface antigen ( HBsAg ) , HBVDNA &gt; Lower Limit Quantification ( LLOQ ) HBsAg negative , antihuman immunodeficiency virus antibody ( HIV Ab ) . 3 . Any current past clinical evidence cirrhosis ascites esophageal varix , prior biopsy show cirrhosis , e.g. , Metavir score &gt; 3 Ishak score &gt; 4 . 4 . Any primary cause liver disease chronic HCV infection , include limited following : Hemochromatosis Alpha1 antitrypsin deficiency Wilson 's disease Autoimmune hepatitis Alcoholic liver disease Drugrelated liver disease Steatosis steatohepatitis liver biopsy coincident HCVrelated change would consider exclusionary unless steatohepatitis consider primary cause liver disease . 5 . Screening laboratory analysis show abnormal kidney , hepatic , hematologic function . 6 . Use know strong inducer cytochrome P450 3A ( CYP3A ) strong inhibitor CYP2C8 within 2 week within 10 halflives , whichever longer , respective medication/supplement prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HCV Infection</keyword>
</DOC>